Clinical trials: Vehicle
Healthy Volunteers
A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of AGN-223575 in healthy subjects.
- Trial name
- NCT02155543
- Testing
- AGN-223575 Formulation A, AGN-223575 Formulation B, AGN-223575 Formulation C
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Allergan
Atopic Dermatitis
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint…
- Trial name
- NCT06880276
- Testing
- 1.5% QLM3003 ointment, 2% QLM3003 ointment
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Vulvovaginal Atrophy
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
Study if WC3011 is effective and safe in the treatment of postmenopausal vaginal dryness due to vulvovaginal atrophy.
- Trial name
- VENUS (NCT01400776)
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 70 sites in United States
- Volunteers
- 722 people
- Sponsor
- Warner Chilcott
Crohns Disease
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
To assess the safety and efficacy of intravenous (IV) PDA001 infused every two weeks for up to 5 total infusions in subjects with Crohn's disease who are refractory to one or more standard Crohn's disease therapies.
- Trial name
- NCT01769755
- Testing
- PDA001
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- Celularity Incorporated
Bacterial Vaginosis
Safety and Efficacy Study to Treat Bacterial Vaginosis
The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.
- Trial name
- NCT01621399
- Testing
- Product 55394
- Where
- 37 sites in United States
- Volunteers
- 651 people
- Sponsor
- Medicis Global Service Corporation
Critical Limb Ischemia
An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)
This study is designed to evaluate the efficacy and safety of ixmyelocel-T, a patient-specific expanded multicellular therapy, for the treatment of patients with critical limb ischemia (CLI).
- Trial name
- REVIVE (NCT01483898)
- Testing
- Ixmyelocel-T
- Where
- 86 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vericel Corporation
Phenylketonurias
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients
The primary objective is of this Phase 1 study is to evaluate the safety and tolerability of daily, multiple, oral doses of CDX-6114 when administered to patients with PKU for 14 days.
- Trial name
- NCT04256655
- Testing
- cohort 1 0.225g, Cohort 2 0.75g, Cohort 3 2.25 g
- Sponsor
- Société des Produits Nestlé (SPN)
Skin Diseases
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
5 Day study to assess how quickly a topical acne product begins to work.
- Trial name
- NCT02052752
- Testing
- 3% Benzoyl Peroxide, Neutrogena Rapid Clear®
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Presbyopia
Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia
This is a Phase IIa study to assess efficacy and safety of STN1013600 ophthalmic solution (0.1%, and 0.3 %), twice daily when compared to Placebo in subjects diagnosed with presbyopia.
- Trial name
- OPSIS (NCT05665387)
- Testing
- 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution
- Where
- 12 sites in United States
- Volunteers
- 79 people
- Sponsor
- Santen Inc.
Discoid Lupus Erythematosus
Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
- Trial name
- NCT00625521
- Testing
- ASF 1096 0.5 % cream applied twice daily, Cream vehicle for ASF 1096 cream applied twice daily
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Astion Pharma A/S
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Phase I Study of Progerinin in Healthy Volunteers
PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability…
- Trial name
- NCT04512963
- Testing
- Progerinin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- PRG Science & Technology Co., Ltd.
Pediculosis
An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
Phase 2 study to assess the safety and effectiveness of a product to treat children and adults with head lice
- Trial name
- NCT01336647
- Testing
- Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Actinic Keratosis
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
- Trial name
- NCT02137785
- Testing
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
- Where
- 13 sites in United States
- Volunteers
- 269 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis
Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis
This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).
- Trial name
- NCT01516515
- Testing
- Vehicle gel, SR-T100 with 2.3% of SM
- Where
- 8 sites in United States
- Volunteers
- 86 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in…
- Conditions
- Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
- Trial name
- NCT03290248
- Testing
- B244 suspension, Vehicle
- Where
- 2 sites in United States, Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Plaque Psoriasis
Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
The objective of the study is to evaluate the safety and efficacy of a topical lotion
- Trial name
- NCT02045277
- Testing
- IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion
- Where
- 18 sites in United States
- Volunteers
- 212 people
- Sponsor
- Bausch Health Americas, Inc.
Dry Eye Disease, Dry Eye
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for…
- Conditions
- Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Trial name
- CAMOMILE-2 (NCT06903611)
- Testing
- CAM-101, Vehicle Control
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Cambium Bio Limited
Psoriasis Vulgaris
A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris
The purpose of the study is to compare the anti-psoriatic effect of marketed products with Daivobet® ointment in a plaque test
- Trial name
- NCT00845481
- Testing
- Daivobet® ointment, Betnovat® ointment, Diprosalic ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Pediatric Glaucoma, Elevated IOP in Pediatric Patients
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients
The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma…
- Conditions
- Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients
- Trial name
- NCT01652664
- Testing
- Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle
- Volunteers
- 184 people
- Sponsor
- Alcon Research